New pill aims to lift the fog of bipolar depression

NCT ID NCT02600494

Completed Symptom relief Sponsor: Intra-Cellular Therapies, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medication, lumateperone, to see if it can safely ease depression in people with bipolar I or II disorder. Over 550 adults took either the drug or a placebo for six weeks. Researchers measured changes in depression symptoms using a standard rating scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bipolar depression bipolar disorder bipolar I disorder bipolar II disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BIPOLAR DEPRESSION

Contacts and locations

Locations

Clinical Site

Little Rock, Arkansas, United States
Clinical Site

Rogers, Arkansas, United States
Clinical Site

Cerritos, California, United States
Clinical Site

Culver City, California, United States
Clinical Site

Garden Grove, California, United States
Clinical Site

Lemon Grove, California, United States
Clinical Site

National City, California, United States
Clinical Site

Oakland, California, United States
Clinical Site

Oceanside, California, United States
Clinical Site

Orange, California, United States
Clinical Site

Pico Rivera, California, United States
Clinical Site

Riverside, California, United States
Clinical Site

San Diego, California, United States
Clinical Site

San Marcos, California, United States
Clinical Site

Santa Rosa, California, United States
Clinical Site

Colorado Springs, Colorado, United States
Clinical Site

Bradenton, Florida, United States
Clinical Site

Fort Myers, Florida, United States
Clinical Site

Jacksonville, Florida, United States
Clinical Site

Lauderhill, Florida, United States
Clinical Site

Miami, Florida, United States
Clinical Site

North Miami, Florida, United States
Clinical Site

Orlando, Florida, United States
Clinical Site

Atlanta, Georgia, United States
Clinical Site

Chicago, Illinois, United States
Clinical Site

Hoffman Estates, Illinois, United States
Clinical Site

Lake Charles, Louisiana, United States
Clinical Site

Baltimore, Maryland, United States
Clinical Site

Boston, Massachusetts, United States
Clinical Site

O'Fallon, Missouri, United States
Clinical Site

St Louis, Missouri, United States
Clinical Site

Las Vegas, Nevada, United States
Clinical Site

Berlin, New Jersey, United States
Clinical Site

Cherry Hill, New Jersey, United States
Clinical Site

Marlton, New Jersey, United States
Clinical Site

Toms River, New Jersey, United States
Clinical Site

Brooklyn, New York, United States
Clinical Site

Cedarhurst, New York, United States
Clinical Site

New York, New York, United States
Clinical Site

Rochester, New York, United States
Clinical Site

Staten Island, New York, United States
Clinical Site

Cincinnati, Ohio, United States
Clinical Site

Cleveland, Ohio, United States
Clinical Site

Dayton, Ohio, United States
Clinical Site

Garfield Heights, Ohio, United States
Clinical Site

Oklahoma City, Oklahoma, United States
Clinical Site

Allentown, Pennsylvania, United States
Clinical Site

Norristown, Pennsylvania, United States
Clinical Site

Philadelphia, Pennsylvania, United States
Clinical Site

Memphis, Tennessee, United States
Clinical Site

Austin, Texas, United States
Clinical Site

Dallas, Texas, United States
Clinical Site

Houston, Texas, United States
Clinical Site

Petersburg, Virginia, United States
Clinical Site

Everett, Washington, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.